Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.

• Tác giả: Hussein R Al-Khalidi, Vanita R Aroda, Matthew A Cavender, Tanya Gaynor, Christopher B Granger, Jennifer B Green, Lisa A Kaltenbach, Julienne K Kirk, Monica Levya, Ildiko Lingvay, Renato D Lopes, Melissa L Magwire, Darren K McGuire, Adam J Nelson, Neha J Pagidipati, Jonathan Pak, Ambarish Pandey, Rodica Pop-Busui, Caroline R Richardson, Cagri Senyucel, Alana Washington, Laura Webb
• Ngôn ngữ: eng
• Ký hiệu phân loại: 641.56314 Cooking
• Thông tin xuất bản: United States : American heart journal , 2025
• Bộ sưu tập: NCBI
• ID: 634945

Tóm tắt

 BACKGROUND: SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD)
  for those prescribed, little is known about reasons for discontinuation. METHODS: From the COORDINATE-Diabetes randomized trial database, the frequency and reasons for discontinuation of SGLT2i or GLP-1RA were analyzed. RESULTS: 1045 participants were enrolled 7/2019 to 5/2022
  290 (27.8%) were prescribed SGLT-2i of whom 67 (23.1%) discontinued
  and 118 (11.3%) were prescribed GLP-1RA of whom 38 (32.2%) discontinued. Race, age and sex did not differ among those discontinuing either class. Medicare was more common among those discontinuing vs persisting with SGLT-2i (71.4 vs. 58.1%
  p=0.058) and GLP-1RA (71.1 vs. 49.4%)
  p=0.027). Cost, side effects, and patient choice were common reasons for discontinuation. CONCLUSION: Up to one-third of participants discontinued either an SGLT-2i or GLP-1RA within 12 months of initiating. Efforts to address modifiable contributors to discontinuation are required.